Glaucoma clinical trials at UCSF
6 in progress, 4 open to eligible people
Glaucoma is a disease that damages the eye's optic nerve. UCSF is exploring whether a language-friendly app can improve how patients take their eye drops. One study looks at using less energy in a laser treatment to see if it is just as effective. Another trial tests a device that might protect eye cells during glaucoma treatment.
App-based Instructional Platform to Improve Eye Drop Recall
open to eligible people ages 18 years and up
The goal of this interventional study is to assess whether an in-office, language-concordant instructional app improves drop regimen recall in a population of glaucoma patients who are on multi-drop regimens. Participants will be divided into two groups -- those who use the app and those who do not. The app will have narrated information regarding the drop regimen, a quiz to test understanding of the regimen, and will enable a graphical printout of the eye drops and schedule. At one month, both groups will be assessed on their eye drop regimen recall.
San Francisco, California
Clarifying the Optimal Application of SLT Therapy Trial
open to eligible people ages 18 years and up
The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it.
San Francisco, California and other locations
Nanodropper Device on Intraocular Pressure in Patients With Glaucoma
open to eligible people ages 18 years and up
Glaucoma is the leading cause of irreversible blindness worldwide. Previous studies demonstrate that smaller eye drops used in the treatment of glaucoma are just as efficacious as their larger counterparts. The proposed study hopes to demonstrate the non-inferiority of using Nanodropper to lower intraoccular pressure (IOP) in glaucoma patients compared to standard of care eye drops.
San Francisco, California
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
open to eligible people ages 18 years and up
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial (DECLARE) is a multi-center, outcome-masked, randomized clinical trial. The purpose of this study is to compare glaucoma drainage device implantation in the anterior chamber (front part of the eye) and sulcus (small space between iris and front chamber of the eye) in efforts to minimize cell loss in the eye.
San Francisco, California and other locations
Glaucoma Screening to Enhance At-Risk Californians' Health
Sorry, not yet accepting patients
The vast majority of glaucoma cases in the United States go undetected and untreated until the late stages of the disease. Open-angle glaucoma is a progressive condition that is asymptomatic in its early to moderate stages and may be amenable to screening through telemedicine-based approaches. This study is a randomized trial to evaluate whether glaucoma screening with established tests (e.g., optical coherence tomography, fundus photography, and tonometry) is more effective for detecting undiagnosed glaucoma cases compared to education alone or delayed intervention.
San Francisco, California
Strategies for Improving Linkage-to-Care After Eye Disease Screening
Sorry, not yet accepting patients
The goal of this randomized, parallel-group, controlled trial is to compare methods of enhancing linkage-to-care for participants in the Village Integrated Eye Worker II (VIEW II) trial who are referred to the eye hospital following eye disease screening. Participants who are referred to the hospital at an eye screening visit will be randomized to three different linkage-to-care interventions: (1) text message reminders, (2) reminders from community health workers, or (3) no intervention. The primary outcome of the trial will be whether or not the participant presented to the eye hospital for a referral visit by 21 days following screening.
San Francisco, California
Our lead scientists for Glaucoma research studies include Ying Han, MD Yvonne Ou, MD Jeremy D Keenan, MD, MPH Frank Brodie.
Last updated: